Finance

Beta
Lists
UTHR:NASDAQ
United Therapeutics Corp
547,69 $
0,00%
(0,00) 1D
4 հնս, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for UTHR...
Mkt. cap
23,25 մլրդ
Avg. vol.
434,99 հզր
Volume
2,00
P/E ratio
20,21
52-wk high
609,35 $
52-wk low
272,12 $
EPS
27,09 $
Beta
0,57
Shares outstanding
42,45 մլն
No. of employees
1 հզր
Mkt. cap
23,25 մլրդ
Avg. vol.
434,99 հզր
Volume
2,00
P/E ratio
20,21
52-wk high
609,35 $
52-wk low
272,12 $
EPS
27,09 $
Beta
0,57
Shares outstanding
42,45 մլն
No. of employees
1 հզր
Analyst outlook
Analyst Ratings
Based on 10 analysts giving stock ratings to UTHR in the past 3 months
Strong Buy
Buy
8
Hold
2
Sell
0
12 month forecast
Based on 10 Wall Street analysts offering 12 month price targets for UTHR in the last 3 months.
Highest
Current 547,69 $
738,00 $ (+34,75%)
Average
665,90 $ (+21,58%)
Lowest
516,00 $ (-5,79%)
News stories
From sources across the web
Profile
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire. Wikipedia
About United Therapeutics Corp
CEO-
Employees1,4 հզր
Founded1996
HeadquartersՍիլվեր Սփրինգ, Մերիլենդ, Միացյալ Նահանգներ
Sector-
Websiteunither.com
Last report
06 մյս, 2026 թ.
Fiscal period
Q1 2026
EPS / Est. (USD)
5,82 $ / 7,04 $
-17,38%miss
Revenue / Est. (USD)
781,50 մլն / 797,38 մլն
-1,99%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 թ. հնս
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
Revenue
798,60 մլն
799,50 մլն
790,20 մլն
781,50 մլն
Cost of goods sold
87,60 մլն
100,90 մլն
103,40 մլն
133,40 մլն
Cost of revenue
87,60 մլն
100,90 մլն
103,40 մլն
133,40 մլն
Research and development expenses
134,00 մլն
127,50 մլն
139,50 մլն
138,20 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
190,80 մլն
181,80 մլն
189,90 մլն
184,10 մլն
Operating expense
324,80 մլն
309,30 մլն
329,40 մլն
322,30 մլն
Total operating expenses
412,40 մլն
410,20 մլն
432,80 մլն
455,70 մլն
Operating income
386,20 մլն
389,30 մլն
357,40 մլն
325,80 մլն
Other non operating income
3,90 մլն
300,00 հզր
800,00 հզր
15,30 մլն
EBT including unusual items
408,40 մլն
438,00 մլն
444,00 մլն
318,30 մլն
EBT excluding unusual items
434,10 մլն
433,00 մլն
398,30 մլն
379,90 մլն
Income tax expense
98,90 մլն
99,30 մլն
79,70 մլն
43,40 մլն
Effective tax rate
24,22%
22,67%
17,95%
13,63%
Other operating expenses
-
-
-
-
Net income
309,50 մլն
338,70 մլն
364,30 մլն
274,90 մլն
Net profit margin
38,76%
42,36%
46,10%
35,18%
Earnings per share
6,41
7,16
7,70
5,82
Interest and investment income
51,30 մլն
46,40 մլն
43,20 մլն
41,80 մլն
Interest expense
-7,30 մլն
-3,00 մլն
-3,10 մլն
-3,00 մլն
Net interest expenses
44,00 մլն
43,40 մլն
40,10 մլն
38,80 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
407,30 մլն
411,20 մլն
380,20 մլն
348,40 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer